ET
Energy Transfer LP Common Units
stockNYSE

But you aren't an editable derivative of the most heavily shorted stock ever, and haven't become the most heavily shorted derivative ever. Literally, my CEO can just change the terms at 3:59 pm ET, and make them a warrant with a $28 strike at to expire in a month. Those warrants will go from $0.17 to $17 in a week. And if toy don't understand that already, I can't brie force it into your brain lol. Why would I not bet on the greatest piece of idiosyncratic risk, with the highest upside potential, to ever exist? Genuinely, it's stupid not to.

**No Active BanBet** | W | L | Win Rate | |:---:|:---:|:---:| | 10 | 10 | 50% | *Banned from banbets until Sun 5:57 PM ET*

**No Active BanBet** | W | L | Win Rate | |:---:|:---:|:---:| | 4 | 1 | 80% | *Banned from banbets until Tue 9:05 AM ET*

Hello guys, Does anyone know the daily snapshot/cutoff time for these LSEG historical series? I downloaded them through the Workspace Excel function `RDP.HistoricalPricing`, using `INTERVAL:P1D`, `TIMEZONE:NYC` and `SOURCE:RFV`: * **SPY.P:** daily `BID` and `ASK`. Do these represent the regular-session close at **16:00 New York time**, or another cutoff? * **USD SOFR OIS zero curve:** daily `DISC_FACT` for RICs such as `USDSROIS1YZ=R` and `USDSROIS12YZ=R`. What valuation time do these discount factors represent, and were they available by **16:00 ET** that day? For the second question, I mean LSEG’s **derived zero curve**, not the New York Fed’s overnight SOFR fixing. I need to align these data with 16:00 SPX/SPXW option observations and found no information about it (might be blind, idk). Documentation or experience with these exact series would be very helpful.

**BanBet Created** ▼ | **Record:** 8W - 6L | Ticker | Target | Entry | Move | Expires | |:---:|:---:|:---:|:---:|:---:| | **MU** | $850.00 (below) | $906.26 | -6.2% | Fri 11:14 PM ET |

No, that's only the twidgets (Nuc ET). I joke. But even though I spent 21 years on subs, and worked with some weird fuckin dudes, I never met a furry or anyone that I thought might have been one.

| Ticker | Target | Entry | Current | Move | Expires | |:---:|:---:|:---:|:---:|:---:|:---:| | **QQQ** ▼ | $700.00 (below) | $724.74 | $707.35 | -3.4% | Wed 3:13 PM ET | | **Record** | 0W - 1L | 0% | - | - | - |

https://preview.redd.it/dbymbbvy4iyh1.png?width=1792&format=png&auto=webp&s=18d040891cd635ad1a7a22e64e8d1562e8209d7f **📊 Key U.S. Economic Data (ET)** **8:30 AM** | Employment Cost Index q/q | Forecast: 0.8% | Previous: 0.9% ⚠️ For informational purposes only. Not financial advice. 📌 #EmploymentCostIndex #LaborCosts

So at 5 pm ET when you still have up to 30 minutes left to give contrary exercise instructions, you're saying that you would be happy to still exercise your 970 call to buy MU at 970 when you could simply lapse the call and buy MU at 960 in after hours? And you would do that because an hour prior the stock was trading at 980? Sorry, that sounds incredibly dumb, so I must have misunderstood you, u/Agile_Cicada_1523 Please point out where I misunderstood you: >Because at 4pm mu was 980. Didnt want time exercise is till 4:30

**No Active BanBet** | W | L | Win Rate | |:---:|:---:|:---:| | 0 | 1 | 0% | *Banned from banbets until Tue 12:24 PM ET*

I think the actual termination of trades is 8PM ET today. That is so Oct 30th is the final day for settlement. The trade termination deadline is so that new buyers will be the holder of record on October 30th.

| Ticker | Target | Entry | Current | Move | Expires | |:---:|:---:|:---:|:---:|:---:|:---:| | **ORCL** ▼ | $119.72 (below) | $133.02 | $134.95 | -10.0% | Tue 7:38 PM ET |

Announcement planned for tomorrow Oct 30 at 8:30 ET!!!

**BanBet Created** ▲ | **Record:** 12W - 4L | Ticker | Target | Entry | Move | Expires | |:---:|:---:|:---:|:---:|:---:| | **RDDT** | $111.27 (above) | $108.03 | +3.0% | Tue 4:34 PM ET |

Cemdisiran shows up twice, in the note under the FDA goal dates and again in the November-guided list, so a skimming reader may count it as two events; keeping one entry and pointing to it from the other spot would fix that. The time zones also change by block (MT for SITC and AASLD, CT for AHA, ET for ACR), which makes the crowded Sunday Nov 8 hard to line up; an ET column next to the local time would help. The ALT time conflict you flagged is worth an edit once one source corrects it. Will the Sunday post carry a changed-since-last-week line? I make ThreadFox. We find relevant Reddit conversations and post for your business. We'll post 3 replies free first, no card; then the $39 Pilot covers seven days and up to 50 posts and replies. No automatic renewal. [https://threadfox.vip/p/ey35n/managed](https://threadfox.vip/p/ey35n/managed)

Yes, I'm sure. They cannot be *traded* tomorrow, not even pre-market. *...the warrants will cease trading under the symbol “GME WS” on the New York Stock Exchange (the “NYSE”) before the markets open on October 30, 2026.* https://www.sec.gov/Archives/edgar/data/1326380/000132638026000064/pressrelease-warrantexpira.htm "before the markets open" includes pre-market. That means GME WS will be halted for trading before the pre-market session begins on Friday, October 30, so you cannot trade the warrants in pre-market on the 30th. If you want to *exercise* them, the deadline remains tomorrow at 5:00 p.m. ET, subject to any earlier cutoff your broker imposes.

What is scheduled over the next ten days, and what happened last week. I build a biotech catalyst calendar ([catalystalert.io](https://catalystalert.io)) and compile this list each week from primary sources: an event is listed only if the company, the FDA or the conference has published its date, and every line links to that source. Times are ET unless noted. If something is wrong or missing, say so in the comments and I'll edit. **FDA goal dates (PDUFA)** |Date|Ticker|Drug · indication|Source| |:-|:-|:-|:-| |Fri Oct 30|INO|INO-3107 (BLA, accelerated approval pathway, standard review) · recurrent respiratory papillomatosis in adults|[8-K](https://www.sec.gov/Archives/edgar/data/1055726/000105572626000024/ino-63026x8kex991.htm) · [tracker](https://catalystalert.io/fda-decision/ino-3107-ino-pdufa-2026-10-30)| |Sun Nov 1|AGIO|Mitapivat sNDA (accelerated approval pathway, priority review) · sickle cell disease|[8-K](https://www.sec.gov/Archives/edgar/data/1439222/000143922226000115/agio-73026xfyxex991earning.htm) · [tracker](https://catalystalert.io/fda-decision/mitapivat-agio-pdufa-2026-11-01)| * INO: the FDA's file-acceptance letter noted a potential review issue on INO-3107's eligibility for accelerated approval ([8-K, Dec 2025](https://www.sec.gov/Archives/edgar/data/1055726/000119312525332322/d78035dex991.htm)). In August the company said the late-cycle meeting and all scheduled pre-licensure inspections were complete. No advisory committee was planned. * AGIO: Nov 1 falls on a Sunday. * Guided to "November 2026" with no day: cemdisiran (REGN / ALNY) in generalized myasthenia gravis ([Alnylam Q3](https://www.sec.gov/Archives/edgar/data/1178670/000117867026000074/alny2026q3earningsrelease.htm)). * A goal date is a deadline, not the decision day: last week the FDA approved bepirovirsen on Oct 20, six days before its Oct 26 goal date ([GSK, Apr 2026](https://www.gsk.com/en-gb/media/press-releases/bepirovirsen-accepted-for-priority-review-and-granted-breakthrough-therapy-designation-by-the-us-fda/)). **FDA advisory committee** * Fri Oct 30, 8:30 am – 3 pm: Dermatologic and Ophthalmic Drugs Advisory Committee on atropine 0.01% (SYD-101) for slowing myopia progression in children. The sponsor, Sydnexis, is private. ([FDA](https://www.fda.gov/advisory-committees/advisory-committee-calendar/october-30-2026-dermatologic-and-ophthalmic-drugs-advisory-committee-meeting-announcement-10302026)) **Conference data in the window** *SITC, Phoenix, Nov 4–8.* Regular abstracts go public Tue Nov 3 at 9 am, late-breaking abstracts Fri Nov 6 at 9 am ([SITC](https://www.sitcancer.org/2026/press/information)). |Date (MT)|Ticker|What|Source| |:-|:-|:-|:-| |Fri Nov 6, 10:04 am|ELTX|ELI-002 7P, randomized Phase 2 AMPLIFY-7P, KRAS-mutated pancreatic cancer (plenary)|[PR](https://elicio.com/press_releases/elicio-therapeutics-to-present-phase-2-amplify-7p-results-at-the-sitc-2026-annual-meeting/)| |Sat Nov 7, 1:45 pm|IMCR|Brenetafusp + KIMMTRAK, Phase 1 data, metastatic uveal melanoma (late-breaking oral; company release Fri Nov 6, noon ET)|[PR](https://www.immunocore.com/investors/news/press-releases/detail/137/immunocore-will-present-phase-1-data-for-brenetafusp-plus-kimmtrak-tebentafusp-tebn-in-metastatic-uveal-melanoma-during-a-late-breaking-oral-session-at-the-2026-sitc-meeting)| |Sat Nov 7, 4:30 pm|MDNAF|MDNA11 ± pembrolizumab, Phase 1/2 ABILITY-1 topline, GI cancers (oral)|[PR](https://www.globenewswire.com/news-release/2026/10/05/3374618/0/en/medicenna-announces-oral-presentation-of-topline-data-from-the-phase-1-2-ability-1-study-of-mdna11-at-sitc-2026.html)| *AASLD The Liver Meeting, Denver, Nov 5–9.* Late-breaking sessions are on Sun Nov 8. |Date (MT)|Ticker|What|Source| |:-|:-|:-|:-| |Sun Nov 8, 11:15 am|NVO|Efruxifermin, SYMMETRY, AI-based histology (oral 0066)|[Novo](https://sciencehub.novonordisk.com/congresses/aasld2026.html)| |Sun Nov 8|ALT|Pemvidutide, Phase 2b IMPACT 48-week non-invasive test responses, MASH (Clinical Trial Pipeline session; the company release says 11:45 am, the AASLD session page 2:45 pm)|[PR](https://ir.altimmune.com/news-releases/news-release-details/altimmune-present-new-data-pemvidutide-serious-liver-diseases)| |Sun Nov 8, 2:15 pm|DTIL|PBGENE-HBV, Phase 1 ELIMINATE-B, chronic hepatitis B (late-breaking oral)|[PR](https://investor.precisionbiosciences.com/news-releases/news-release-details/precision-biosciences-announces-late-breaking-oral-0)| |Sun Nov 8, 2:15 pm|VIR|Elebsiran + tobevibart, Phase 2 SOLSTICE week 96, hepatitis delta (oral)|[PR](https://investors.vir.bio/news/news-details/2026/Vir-Biotechnology-to-Present-Expanded-Phase-2-SOLSTICE-Results-for-Elebsiran-and-Tobevibart-in-Hepatitis-Delta-at-AASLDs-The-Liver-Meeting-2026/default.aspx)| |Sun Nov 8, 5:00 pm|GILD|Seladelpar, Phase 3 IDEAL, primary biliary cholangitis (late-breaking oral)|[PR](https://www.gilead.com/news/news-details/2026/gilead-to-present-new-data-on-treatment-response-and-long-term-management-of-rare-liver-diseases-at-the-liver-meeting-2026)| *AHA Scientific Sessions, Chicago, Nov 6–9.* |Date (CT)|Ticker|What|Source| |:-|:-|:-|:-| |Sat Nov 7, 8:30 am|NVO; NVS / IONS|Full results of ZEUS (ziltivekimab) and Lp(a)HORIZON (pelacarsen). Both missed their primary endpoint in topline releases (Jul 31 and Sep 4).|[AHA](https://professional.heart.org/en/meetings/scientific-sessions/programming/late-breaking-science) · [Novo](https://www.sec.gov/Archives/edgar/data/353278/000117184326005109/f6k_073126.htm) · [Novartis](https://www.sec.gov/Archives/edgar/data/1114448/000117184326005896/f6k_090426.htm)| |Sun Nov 8, 10:10 am|LGVN|Laromestrocel, Phase 2b ELPIS II, hypoplastic left heart syndrome|[PR](https://www.sec.gov/Archives/edgar/data/1721484/000121390026112508/ea030920801ex99-1.htm)| |No slot given|ALNY|Vutrisiran, HELIOS-B two-year open-label extension, ATTR-CM|[Q3](https://www.sec.gov/Archives/edgar/data/1178670/000117867026000074/alny2026q3earningsrelease.htm)| *ACR Convergence, Orlando, Nov 6–11.* Abstract sessions start Sun Nov 8. |Date (ET)|Ticker|What|Source| |:-|:-|:-|:-| |Sun Nov 8, 9:15 am|JNJ|Nipocalimab, Phase 2 in SLE (#0875); Phase 2 SPIREA in myositis at 1:45 pm ([\#0905](https://acrabstracts.org/abstract/efficacy-and-safety-of-nipocalimab-in-participants-with-idiopathic-inflammatory-myopathies-results-from-the-phase-2-spirea-trial-through-52-weeks/))|[ACR](https://acrabstracts.org/abstract/nipocalimab-in-sle-first-in-class-efficacy-and-safety-results-demonstrating-proof-of-concept-for-fcrn-blockade-from-a-phase-2-study/)| |Sun Nov 8, 11:15 am|LLY|Retatrutide, 68-week Phase 3 in knee osteoarthritis with obesity (plenary, #0871)|[ACR](https://acrabstracts.org/abstract/retatrutide-once-weekly-for-the-treatment-of-knee-osteoarthritis-pain-and-obesity-results-from-a-68-week-phase-3-randomized-clinical-trial/)| |Sun Nov 8, 1:15 pm|NKTX|NKX019, Phase 1/2, idiopathic inflammatory myopathy (#0903)|[PR](https://acrabstracts.org/abstract/preliminary-safety-pk-pd-and-clinical-activity-of-nkx019-an-allogeneic-cd19-targeted-car-nk-cell-therapy-in-idiopathic-inflammatory-myopathy-results-from-an-ongoing-phase-1-2-open-label-mult/)| |Sun Nov 8, 2:15 pm|ROIV|Brepocitinib, Phase 3 VALOR in dermatomyositis (#0907)|[ACR](https://acrabstracts.org/abstract/achievement-of-low-disease-activity-and-remission-in-dermatomyositis-patients-treated-with-brepocitinib-analyses-from-the-phase-3-valor-trial/)| ASH 2026 abstracts go online Wed Nov 4 at 9 am; the meeting is Dec 12–15 ([ASH](https://www.hematology.org/meetings/annual-meeting/abstracts)). **Guided to "November 2026", no day given** * ABOS: ALTITUDE-AD Phase 2 topline, sabirnetug in early Alzheimer's ([8-K](https://www.sec.gov/Archives/edgar/data/1576885/000162828026067129/abos-20261026xexx991.htm)) * IBRX: QUILT-2.005 cohort A topline, ANKTIVA + BCG in BCG-naïve bladder cancer ([PR](https://immunitybio.com/immunitybio-announces-database-lock-for-registrational-trial-of-locally-delivered-chemotherapy-free-anktiva-plus-bcg-in-bcg-naive-non-muscle-invasive-bladder-cancer/)) * PHAR: leniolisib Phase 2 in CVID with immune dysregulation ([Q3](https://www.pharming.com/our-news/pharming-reports-third-quarter-2026-financial-results)) * REGN / ALNY: cemdisiran FDA goal date, generalized myasthenia gravis ([Alnylam Q3](https://www.sec.gov/Archives/edgar/data/1178670/000117867026000074/alny2026q3earningsrelease.htm)) **Last week (Oct 19–29)** FDA approvals. I found no complete response letter in that period's filings. |Date|Ticker|Approval|Source| |:-|:-|:-|:-| |Oct 19|GSK|Jemperli, dMMR/MSI-H locally advanced rectal cancer (accelerated)|[6-K](https://www.sec.gov/Archives/edgar/data/1131399/000165495426009036/a5712z.htm)| |Oct 20|GSK / IONS|Hibsago (bepirovirsen), chronic hepatitis B|[FDA](https://www.fda.gov/news-events/press-announcements/fda-approves-first-its-kind-chronic-hepatitis-b-treatment)| |Oct 22|AZN|Ultomiris, IgA nephropathy (accelerated)|[6-K](https://www.sec.gov/Archives/edgar/data/901832/000165495426009093/a9580z.htm)| |Oct 22|AMGN|Pavblu (aflibercept-ayyh) designated interchangeable with Eylea|[FDA letter](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/761298Orig2s000ltr.pdf)| |Oct 23|ABBV|Skyrizi subcutaneous induction, Crohn's disease|[PR](https://news.abbvie.com/2026-10-23-U-S-FDA-Approves-Subcutaneous-Induction-Regimen-for-AbbVies-SKYRIZI-R-risankizumab-rzaa-for-Adults-With-Moderately-to-Severely-Active-Crohns-Disease)| |Oct 23|NVO|Awiqli (once-weekly insulin icodec), type 2 diabetes from age 10|[FDA](https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-once-weekly-insulin-type-2-diabetes-mellitus-pediatric-patients)| |Oct 26|PFE|Talzenna + Xtandi, HRR gene-mutated metastatic castration-sensitive prostate cancer|[FDA](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-talazoparib-enzalutamide-metastatic-androgen-pathway-modulation-naive-or-sensitive)| Also: BHVN's troriluzole NDA resubmission (spinocerebellar ataxia) was accepted with a Q1 2027 goal date, and the FDA plans an advisory committee ([8-K](https://www.sec.gov/Archives/edgar/data/1935979/000193597926000083/bhvn-20261022.htm)). Phase 3 toplines (plus one Phase 2), in the companies' words: |Date|Ticker|Trial · result|Source| |:-|:-|:-|:-| |Oct 19|IRON|Bitopertin, APOLLO (EPP incl. XLP): met all primary and secondary endpoints|[8-K](https://www.sec.gov/Archives/edgar/data/1816736/000119312526424649/d156263dex991.htm)| |Oct 19|EYPT|Duravyu, LUCIA (wet AMD): did not achieve non-inferiority on BCVA vs aflibercept 2 mg|[8-K](https://www.sec.gov/Archives/edgar/data/1314102/000119312526424644/eypt-ex99_1.htm)| |Oct 19|MANE|VDPHL01 (oral extended-release minoxidil), male pattern hair loss: met co-primary endpoints|[8-K](https://www.sec.gov/Archives/edgar/data/1827635/000182763526000036/exhibit991datarelease101926.htm)| |Oct 21|ROIV|Brepocitinib, CLARITY-1 and -2 (non-infectious uveitis): met the primary endpoint in both|[8-K](https://www.sec.gov/Archives/edgar/data/1635088/000114036126040332/ef20084121_ex99-1.htm)| |Oct 22|ABBV|Lutikizumab, INTREPID (hidradenitis suppurativa): HiSCR75 at week 16, 31.4% vs 23.4%|[PR](https://news.abbvie.com/2026-10-22-AbbVie-Announces-Topline-Results-from-the-Phase-3-INTREPID-Trial-Showing-Lutikizumab-Significantly-Improved-Signs-and-Symptoms-of-Disease-in-Patients-with-Hidradenitis-Suppurativa)| |Oct 23|GMAB|Rina-S, RAINFOL-02 (platinum-resistant ovarian cancer): PFS HR 0.29, OS HR 0.43|[6-K](https://www.sec.gov/Archives/edgar/data/1434265/000143426526000138/gmab_20261023xex99d1.htm)| |Oct 26|BNTX|Trastuzumab pamirtecan, DYNASTY-Breast02 (HR+/HER2-low): PFS met, "statistically significant, yet modest"; OS immature; higher ILD rate|[6-K](https://www.sec.gov/Archives/edgar/data/1776985/000177698526000074/a991261025_bntxdbxtpamxtop.htm)| |Oct 26|HCM|Savolitinib + osimertinib, SAFFRON (EGFRm NSCLC after Tagrisso): PFS HR 0.55, OS HR 0.68|[6-K](https://www.sec.gov/Archives/edgar/data/1648257/000164825726000068/hcm-ex99d1.htm)| |Oct 27|PFE|Elrexfio monotherapy, MagnetisMM-32 (relapsed/refractory myeloma): met PFS primary endpoint|[PR](https://s206.q4cdn.com/795948973/files/doc_news/Pfizers-ELREXFIO-Outperforms-Standard-Regimens-and-Meets-Primary-Endpoint-in-Phase-3-Study-in-Relapsed-or-Refractory-Multiple-Myeloma-2026.pdf)| |Oct 27|VNDA|Tradipitant, Study 3601 (GLP-1-induced vomiting): 43.0% vs 58.5% vomited, p=0.006|[PR](https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-positive-results-from-study-3601-of-nereus-tradipitant-for-prevention-of-glp-1induced-vomiting-302920054.html)| |Oct 28|LLY|Retatrutide vs Ozempic 2 mg, TRANSCEND-T2D-2: A1C −2.2% vs −1.8%; weight −19.5%/−20.9% vs −9.4%|[PR](https://www.prnewswire.com/news-releases/lillys-retatrutide-delivered-greater-a1c-reduction-and-more-than-double-the-weight-loss-of-ozempics-highest-approved-dose-in-head-to-head-trial-302921328.html)| |Oct 28|GMAB|Petosemtamab + pembrolizumab, LiGeR-HN1 (1L head and neck): OS HR 0.50 at the first interim|[6-K](https://www.sec.gov/Archives/edgar/data/1434265/000143426526000140/gmab_20261028xex99d1.htm)| |Oct 28|GERN|Imetelstat, IMpactMF (relapsed/refractory myelofibrosis): stopped; the DMC said it was unlikely to meet its OS endpoint|[8-K](https://www.sec.gov/Archives/edgar/data/886744/000119312526436272/d43013dex991.htm)| |Oct 20|RAPP|RAP-219, Phase 2 in acute bipolar mania: met primary endpoint (YMRS −3.1 vs placebo, p=0.045)|[8-K](https://www.sec.gov/Archives/edgar/data/2012593/000119312526425647/d185134dex991.htm)| How this list is made: dates and results come from company releases, SEC filings, FDA pages and conference programs. Third-party calendars are used only to find leads, and anything I could not confirm at a primary source is left out. Goal dates are targets: the FDA can act earlier or extend. Not investment advice. Disclosure: I'm the developer behind [catalystalert.io](https://catalystalert.io), a biotech catalyst calendar where every date carries its source and a confidence label. I'll post this list every Sunday if it's useful.

thanks for posting this. so the PR comes out before the open and the call is 8:30 ET. they don't say what the milestone is yet, so i'll read the actual release when it's out

"WILMINGTON, Del., Oct. 29, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, “NRx” or “the Company”), a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA receptor platform for the treatment of central nervous system disorders, today announced that it will host a conference call at **8:30 a.m. ET on Friday, October 30, 2026,** to discuss a regulatory milestone for its Preservative-Free Ketamine program and next steps on the commercial launch. The Company will issue a press release with details before the market opens that morning."

| Ticker | Target | Entry | Current | Move | Expires | |:---:|:---:|:---:|:---:|:---:|:---:| | **QQQ** ▼ | $700.00 (below) | $724.74 | $714.96 | -3.4% | Wed, Nov 4, 3:13 PM ET | | **Record** | 0W - 1L | 0% | - | - | - |

**BanBet Created** ▼ | **Record:** 0W - 2L | Ticker | Target | Entry | Move | Expires | |:---:|:---:|:---:|:---:|:---:| | **RDDT** | $110.00 (below) | $128.83 | -14.6% | Fri 3:17 PM ET |

Depends on how old you are and what you are trying to do with the account. As an example I have a brokerage account that I use as my dividend account in addition to my 401k, trad and roth IRAs, HSA, etc. that are all set to large cap growth, so my dividend account is a small fraction of the other accounts. My goal with that brokerage account is to make a dividend income account that may allow me to retire a few years early. Presently since I'm at a minimum of 10 years away from retirement (14-17 is more realistic) I still have a bunch in VOO and QQQM for growth, but new money doesn't often get allocated there. For dividends I want to make sure that my future income is well diversified, so I've got a large allocation to SCHD for Domestic and VYMI for International, then much smaller chunks in bdcs like MAIN, reits like RLTY, O or DOC, PFFA for preferred shares, couple of bond funds like PTY, a small smattering of CC funds like GPIQ, DIVO, IDVO all with small allocations. I also have a very small investment in FOXY, OVL and KGLD (about .5% of that account each) as I otherwise wouldn't have exposure to forex, CSP funds or gold. Lastly I hold a small number of individual stocks in that account that have done particularly well for me over the past few years like KO, SWK and NEE, and some that haven't like T. Used to hold ET for a midstream oil, but dislike the additional tax filings and am looking to replace it with something since it actually did really well for me and I otherwise don't have exposure to oil outside of SCHD. Regardless of how much you put in, I'd suggest working out what allocation blend you want for the year and setup a recurring investment. Presently my new money is a few hundred a paycheck split between \~12 tickers, $25 bucks here, $40 bucks there, etc. which over time allows me to DCA into the diversity I'm looking for.

**LIVE** Tonight 9PM ET - my earnings call Make sure to tune in

# Intel Q3 2026 earnings page * [https://www.intc.com/news-events/ir-calendar/detail/20261029-q3-2026-intel-corporation-earnings-conference-call](https://www.intc.com/news-events/ir-calendar/detail/20261029-q3-2026-intel-corporation-earnings-conference-call) # Earnings release * TBA # Slides * TBA # Earnings call / webcast (2PM PT / 5PM ET) * [https://edge.media-server.com/mmc/p/wmusrcit/](https://edge.media-server.com/mmc/p/wmusrcit/) # Transcripts * TBA # Previous discussions |Q1|Q2|Q3|Q4| |:-|:-|:-|:-| |[2026-Q1](https://www.reddit.com/r/AMD_Stock/comments/1stomif/intel_q1_2026_earnings_discussion/)|[2026-Q2](https://www.reddit.com/r/AMD_Stock/comments/1vfg86d/amd_q2_2026_earnings_discussion/)|\---|\---| |[2025-Q4](https://www.reddit.com/r/AMD_Stock/comments/1qk1oyr/intel_q4_2025_earnings_discussion/)|[2025-Q3](https://www.reddit.com/r/AMD_Stock/comments/1oe8rup/intel_q3_2025_earnings_discussion/)|[2025-Q2](https://www.reddit.com/r/AMD_Stock/comments/1m8ev5t/intel_reports_secondquarter_2025_financial_results/)|[2025-Q1](https://www.reddit.com/r/AMD_Stock/comments/1k6xevr/intel_q1_2025_earnings_discussion/)| |[2024-Q4](https://www.reddit.com/r/AMD_Stock/comments/1idt3dd/intel_q4_2024_earnings_discussion/)|[2024-Q3](https://www.reddit.com/r/AMD_Stock/comments/1gezl0m/amd_q3_2024_earnings_discussion/)|[2024-Q2](https://www.reddit.com/r/AMD_Stock/comments/1ehlt00/intel_q2_2024_earnings_discussion/)|[2024-Q1](https://www.reddit.com/r/AMD_Stock/comments/1cczy0o/intel_q1_2024_earnings_discussion/)| |[2023-Q4](https://www.reddit.com/r/AMD_Stock/comments/19ffhtm/intel_q4_2023_earnings_discussion/)|[2023-Q3](https://www.reddit.com/r/AMD_Stock/comments/17h15v8/intel_q3_2023_earnings_discussion/)|[2023-Q2](https://www.reddit.com/r/AMD_Stock/comments/15bcavd/intel_earnings_thread_20230727/)|[2023-Q1](https://www.reddit.com/r/AMD_Stock/comments/1314sht/intel_earnings_q1fy23_earnings_thread/)| |[2022-Q4](https://www.reddit.com/r/AMD_Stock/comments/10m2u2z/intel_q4_2022_earnings_thread/)|[2022-Q3](https://www.reddit.com/r/AMD_Stock/comments/yexcn8/intel_q3_2022_earnings_discussion_thread/)|[2022-Q2](https://www.reddit.com/r/AMD_Stock/comments/wabeoh/intel_q2_2022_earnings_discussion_thread/)|[2022-Q1](https://www.reddit.com/r/AMD_Stock/comments/ue3sii/intel_q1_2022_earnings_discussion_thread/)|

**BanBet Created** ▼ | **Record:** 0W - 1L | Ticker | Target | Entry | Move | Expires | |:---:|:---:|:---:|:---:|:---:| | **AMZN** | $220.00 (below) | $246.46 | -10.7% | Fri 12:41 PM ET |